New release of neXtProt with ENYO Pharma human interactome data

Published on 04/08/2020

ENYO Pharma and the CALIPHO group at SIB Swiss Institute of Bioinformatics are pleased to announce the neXtProt data release 2020-07-17, that integrates the human protein interactome curated by the company as “GOLD” data. This dataset includes 108,000 descriptions of protein interactions from 324 papers with the capture of the experimental method (PSI-MI). When the sequence used in the protein-protein interaction experiment is known, this information has been collected and is available in neXtProt as interaction mapping annotations.

Read next in 'Latest news'

• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
• New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters